Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 12 (3) |
| Completed vs Stopped Early | 3 / 1 (6.3%) |
| Median Closed Actual Enrollment | 80 participants |
| Physical Hospital Site Disclosure | 99.8% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | 8 |
| Emory Winship Cancer Institute | Atlanta, GA | 8 |
| Massachusetts General Hospital | Boston, MA | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Phase II/III | ACTIVE NOT RECRUITING |
| NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-N | Phase III | ACTIVE NOT RECRUITING |
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Phase II | ACTIVE NOT RECRUITING |
| NCT03559699 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Agios Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.